Transforming Drug Development with Artificial Intelligence: Reflections on Applications in Safety and Clinical Planning

Pharmaceutical development faces moun-ting pressure from escalating costs, lengthy timelines, and stringent regulatory oversi-ght. Artificial intelligence (AI) has emerged as a potential catalyst for redesigning this end‑to‑end process. This reflective article critically reviews the current state and fu-ture trajectory of AI in the pharmaceutical industry, illustrated by two projects led by the author: (i) an AI-empowered pharmaco-vigilance framework that forecasts adver-se events before clinical manifestation and (ii) a dynamic optimization algorithm that redefines the strategy for selecting and ac-tivating clinical sites. Methodological cha-llenges (data quality, interpretability, bias) and lessons learned for scalable adoption are discussed, as well as requirements for governance and regulatory collaboration. Evidence suggests that AI can reduce costs, compress timelines, and enhance patient safety; however, its ultimate value will de-pend on rigorous principles of transparen-cy, validation, and ethical oversight.